These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 32901908)
1. Therapeutic effect of presurgical treatment with longacting octreotide (Sandostatin® LAR®) in patients with acromegaly. Bolanowski M; Zgliczyński W; Sowiński J; Bałdys-Waligórska A; Bednarek-Tupikowska G; Witek P; Zieliński G; Liebert W; Siemińska L; Andrysiak-Mamos E; Marek B; Kajdaniuk D; Malicka J; Rosiek V; Jawiarczyk-Przybyłowska A; Investigators CB Endokrynol Pol; 2020; 71(4):285-291. PubMed ID: 32901908 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of Sandostatin LAR (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy. Ayuk J; Stewart SE; Stewart PM; Sheppard MC; Clin Endocrinol (Oxf); 2004 Mar; 60(3):375-81. PubMed ID: 15009004 [TBL] [Abstract][Full Text] [Related]
3. Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR. Jenkins PJ; Emery M; Howling SJ; Evanson J; Besser GM; Monson JP Horm Res; 2004; 62(5):227-32. PubMed ID: 15477693 [TBL] [Abstract][Full Text] [Related]
4. Comparison of monthly intramuscular injections of Sandostatin LAR with multiple subcutaneous injections of octreotide in the treatment of acromegaly; effects on growth hormone and other markers of growth hormone secretion. Hunter SJ; Shaw JA; Lee KO; Wood PJ; Atkinson AB; Bevan JS Clin Endocrinol (Oxf); 1999 Feb; 50(2):245-51. PubMed ID: 10396369 [TBL] [Abstract][Full Text] [Related]
5. Clinical and biochemical response following withdrawal of a long-acting, depot injection form of octreotide (Sandostatin-LAR). Stewart PM; Stewart SE; Clark PM; Sheppard MC Clin Endocrinol (Oxf); 1999 Mar; 50(3):295-9. PubMed ID: 10435053 [TBL] [Abstract][Full Text] [Related]
6. Sandostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval. Biermasz NR; van den Oever NC; Frölich M; Arias AM; Smit JW; Romijn JA; Roelfsema F Clin Endocrinol (Oxf); 2003 Mar; 58(3):288-95. PubMed ID: 12608933 [TBL] [Abstract][Full Text] [Related]
7. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue? Jallad RS; Musolino NR; Kodaira S; Cescato VA; Bronstein MD Clin Endocrinol (Oxf); 2007 Aug; 67(2):310-5. PubMed ID: 17555503 [TBL] [Abstract][Full Text] [Related]
8. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Mercado M; Borges F; Bouterfa H; Chang TC; Chervin A; Farrall AJ; Patocs A; Petersenn S; Podoba J; Safari M; Wardlaw J; Clin Endocrinol (Oxf); 2007 Jun; 66(6):859-68. PubMed ID: 17465997 [TBL] [Abstract][Full Text] [Related]
9. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly. McKeage K; Cheer S; Wagstaff AJ Drugs; 2003; 63(22):2473-99. PubMed ID: 14609359 [TBL] [Abstract][Full Text] [Related]
10. Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly. Davies PH; Stewart SE; Lancranjan L; Sheppard MC; Stewart PM Clin Endocrinol (Oxf); 1998 Mar; 48(3):311-6. PubMed ID: 9578821 [TBL] [Abstract][Full Text] [Related]
11. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly. Yang LP; Keating GM Drugs; 2010 Sep; 70(13):1745-69. PubMed ID: 20731479 [TBL] [Abstract][Full Text] [Related]
12. Optimizing medical therapy of acromegaly: beneficial effects of cabergoline in patients uncontrolled with long-acting release octreotide. Jallad RS; Bronstein MD Neuroendocrinology; 2009; 90(1):82-92. PubMed ID: 19439914 [TBL] [Abstract][Full Text] [Related]
13. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial. Colao A; Pivonello R; Rosato F; Tita P; De Menis E; Barreca A; Ferrara R; Mainini F; Arosio M; Lombardi G Clin Endocrinol (Oxf); 2006 Mar; 64(3):342-51. PubMed ID: 16487447 [TBL] [Abstract][Full Text] [Related]
14. Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly. de Herder WW; Taal HR; Uitterlinden P; Feelders RA; Janssen JA; van der Lely AJ Eur J Endocrinol; 2005 Jul; 153(1):67-71. PubMed ID: 15994747 [TBL] [Abstract][Full Text] [Related]
15. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Amato G; Mazziotti G; Rotondi M; Iorio S; Doga M; Sorvillo F; Manganella G; Di Salle F; Giustina A; Carella C Clin Endocrinol (Oxf); 2002 Jan; 56(1):65-71. PubMed ID: 11849248 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of high-dose long-acting repeatable octreotide as monotherapy or in combination with pegvisomant or cabergoline in patients with acromegaly not adequately controlled by conventional regimens: results of an open-label, multicentre study. Colao A; Zgliczyński W; Komorowski J; Kos-Kudła B; Tabarin A; Kerlan V; Minuto FM; Scaroni C; Bolanowski M Endokrynol Pol; 2019; 70(4):305-312. PubMed ID: 31274183 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study. Ronchi CL; Boschetti M; Degli Uberti EC; Mariotti S; Grottoli S; Loli P; Lombardi G; Tamburrano G; Arvigo M; Angeletti G; Boscani PF; Beck-Peccoz P; Arosio M; Clin Endocrinol (Oxf); 2007 Oct; 67(4):512-9. PubMed ID: 17555511 [TBL] [Abstract][Full Text] [Related]
19. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study. Plöckinger U; Quabbe HJ Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331 [TBL] [Abstract][Full Text] [Related]
20. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. Bevan JS; Atkin SL; Atkinson AB; Bouloux PM; Hanna F; Harris PE; James RA; McConnell M; Roberts GA; Scanlon MF; Stewart PM; Teasdale E; Turner HE; Wass JA; Wardlaw JM J Clin Endocrinol Metab; 2002 Oct; 87(10):4554-63. PubMed ID: 12364434 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]